$AKBA
Akebia Therapeutics, Inc. Stock $akba

$akba Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000162828021009696 Filed on May 10, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$52.30M	$88.48M
YoY Change	-40.88%	21.76%
Cost Of Revenue	$34.61M	$27.71M
YoY Change	24.87%	-11.34%
Gross Profit	$17.70M	$60.77M
YoY Change	-70.87%	46.74%
Gross Profit Margin	33.84%	68.68%
Selling, General & Admin	$41.33M	$37.98M
YoY Change	8.81%	10.77%
% of Gross Profit	233.52%	62.51%
Research & Development	$40.61M	$81.23M
YoY Change	-50.01%	-1.36%
% of Gross Profit	229.47%	133.68%
Depreciation & Amortization	$9.520M	$525.0K
YoY Change	1713.33%	19.59%
% of Gross Profit	53.79%	0.86%
Operating Expenses	$82.63M	$119.9M
YoY Change	-31.08%	2.14%
Operating Profit	-$64.94M	-$59.13M
YoY Change	9.83%	-22.17%
Interest Expense	-$4.805M	-$1.972M
YoY Change	143.66%	-326.93%
% of Operating Profit
Other Income/Expense, Net	$161.0K	-$1.622M
YoY Change	-109.93%	-305.06%
Pretax Income	-$69.60M	-$60.75M
YoY Change	14.57%	-19.2%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$69.58M	-$60.75M
YoY Change	14.54%	-16.12%
Net Earnings / Revenue	-133.03%	-68.66%
Basic Earnings Per Share	-$0.45
Diluted Earnings Per Share	-$0.45	-$472.7K
COMMON SHARES
Basic Shares Outstanding	153.8M shares	129.9M
Diluted Shares Outstanding	153.8M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$272.8M	$115.4M
YoY Change	136.4%	-31.33%
Cash & Equivalents	$252.8M	$115.4M
Short-Term Investments	$20.00M	$0.00
Other Short-Term Assets	$12.20M	$8.700M
YoY Change	40.23%	-44.23%
Inventory	$44.81M	$111.9M
Prepaid Expenses
Receivables	$35.23M	$104.9M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$365.0M	$340.8M
YoY Change	7.12%	-1.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.168M	$9.855M
YoY Change	-17.12%	-76.48%
Goodwill	$55.10M	$55.05M
YoY Change	0.09%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$39.64M	$71.92M
YoY Change	-44.89%	-43.85%
Total Long-Term Assets	$263.7M	$447.0M
YoY Change	-41.0%	-17.78%
TOTAL ASSETS
Total Short-Term Assets	$365.0M	$340.8M
Total Long-Term Assets	$263.7M	$447.0M
Total Assets	$628.7M	$787.7M
YoY Change	-20.19%	-11.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$30.54M	$54.38M
YoY Change	-43.84%	257.15%
Accrued Expenses	$123.9M	$124.9M
YoY Change	-0.8%	-9.37%
Deferred Revenue	$18.25M	$34.89M
YoY Change	-47.68%	-29.64%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$172.7M	$214.2M
YoY Change	-19.37%	5.7%
LONG-TERM LIABILITIES
Long-Term Debt	$96.61M	$76.07M
YoY Change	26.99%
Other Long-Term Liabilities	$53.62M	$101.1M
YoY Change	-46.97%	-14.25%
Total Long-Term Liabilities	$150.2M	$76.07M
YoY Change	97.48%	-35.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$172.7M	$214.2M
Total Long-Term Liabilities	$150.2M	$76.07M
Total Liabilities	$414.8M	$290.2M
YoY Change	42.93%	-10.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.247B	-$854.8M
YoY Change	45.89%
Common Stock	$1.461B	$1.251B
YoY Change	16.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$213.9M	$396.4M
YoY Change
Total Liabilities & Shareholders Equity	$628.7M	$787.7M
YoY Change	-20.19%	-11.57%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$69.58M	-$60.75M
YoY Change	14.54%	-16.12%
Depreciation, Depletion And Amortization	$9.520M	$525.0K
YoY Change	1713.33%	19.59%
Cash From Operating Activities	-$70.75M	-$89.59M
YoY Change	-21.03%	-35.05%
INVESTING ACTIVITIES
Capital Expenditures	$59.00K	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$20.00M	$250.0K
YoY Change	7900.0%	-99.78%
Cash From Investing Activities	$19.94M	$245.0K
YoY Change	8039.18%	-99.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$74.48M	$57.35M
YoY Change	29.87%	-496.95%
NET CHANGE
Cash From Operating Activities	-$70.75M	-$89.59M
Cash From Investing Activities	$19.94M	$245.0K
Cash From Financing Activities	$74.48M	$57.35M
Net Change In Cash	$23.67M	-$32.00M
YoY Change	-173.98%	-23.64%
FREE CASH FLOW
Cash From Operating Activities	-$70.75M	-$89.59M
Capital Expenditures	$59.00K	$0.00
Free Cash Flow	-$70.81M	-$89.59M
YoY Change	-20.97%	-35.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001517022
CY2021Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:AccruedLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:AccruedLiabilitiesCurrent
CY2021Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:AccruedLiabilitiesCurrent
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-36352
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	AKEBIA THERAPEUTICS, INC.
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8756903
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	245 First Street
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
CY2021Q1	dei	City Area Code CityAreaCode	617
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	871-2098
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.00001 per share
CY2021Q1	dei	Trading Symbol TradingSymbol	AKBA
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	160115163	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	252765000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	228698000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	19999000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	39992000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	44806000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	61017000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35233000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	26853000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12214000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14877000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	365017000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	371437000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8168000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8622000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	25670000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26876000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	55053000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	55053000	USD
CY2021Q1	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	135159000	USD
CY2020Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	144170000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	39636000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	37981000	USD
CY2021Q1	us-gaap	Assets Assets	628703000	USD
CY2020Q4	us-gaap	Assets Assets	644139000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	30537000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	41308000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	123889000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	130624000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	18253000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	15214000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	172679000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	187146000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	19299000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	25345000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	23185000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	24621000	USD
CY2021Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	2500000	USD
CY2020Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	2420000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	96607000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	96378000	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	46925000	USD
CY2020Q4	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	0	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	53617000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	60611000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	414812000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	396521000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	158520089	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	158520089	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	148074085	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	148074085	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2021Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1460971000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1425115000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	9000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	13000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1247091000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1177511000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	213891000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	247618000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	628703000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	644139000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	52304000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	88478000	USD
CY2021Q1	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	25595000	USD
CY2020Q1	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	18613000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	9011000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	9100000	USD
CY2021Q1	us-gaap	Cost Of Revenue CostOfRevenue	34606000	USD
CY2020Q1	us-gaap	Cost Of Revenue CostOfRevenue	27713000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40611000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	81231000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	41328000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	37983000	USD
CY2021Q1	akba	License Expense LicenseExpense	695000	USD
CY2020Q1	akba	License Expense LicenseExpense	676000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	82634000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	119890000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-64936000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-59125000	USD
CY2021Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4805000	USD
CY2020Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1972000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	161000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	350000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-69580000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-60747000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.45
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.47
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	153820809	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	128395163	shares
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-69580000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-60747000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-4000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-69584000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-60747000	USD
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	394757000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	56575000	USD
CY2020Q1	akba	Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan	451000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4916000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	412000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-60747000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	396364000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	247618000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	29498000	USD
CY2021Q1	akba	Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan	367000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5992000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-4000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-69580000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	213891000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-69580000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-60747000	USD
CY2021Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	513000	USD
CY2020Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	525000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9011000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9100000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	11000	USD
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Noncash Interest Expense Income ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome	2162000	USD
CY2020Q1	akba	Contractual Arrangement Royalties Agreement Noncash Interest Expense Income ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome	0	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Noncash Royalty Revenue ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue	20000	USD
CY2020Q1	akba	Contractual Arrangement Royalties Agreement Noncash Royalty Revenue ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue	0	USD
CY2021Q1	akba	Noncash Interest Expense NoncashInterestExpense	229000	USD
CY2020Q1	akba	Noncash Interest Expense NoncashInterestExpense	437000	USD
CY2021Q1	us-gaap	Straight Line Rent StraightLineRent	494000	USD
CY2020Q1	us-gaap	Straight Line Rent StraightLineRent	647000	USD
CY2021Q1	akba	Fair Value Adjustment To Inventory FairValueAdjustmentToInventory	21575000	USD
CY2020Q1	akba	Fair Value Adjustment To Inventory FairValueAdjustmentToInventory	11180000	USD
CY2021Q1	us-gaap	Inventory Write Down InventoryWriteDown	5075000	USD
CY2020Q1	us-gaap	Inventory Write Down InventoryWriteDown	139000	USD
CY2021Q1	akba	Excess Inventory Purchase Commitments Expense Reversal ExcessInventoryPurchaseCommitmentsExpenseReversal	-8945000	USD
CY2020Q1	akba	Excess Inventory Purchase Commitments Expense Reversal ExcessInventoryPurchaseCommitmentsExpenseReversal	0	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5992000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4916000	USD
CY2021Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	80000	USD
CY2020Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	90000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8380000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	66008000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	19193000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8163000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2268000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1898000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1361000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-46000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4912000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	20470000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4877000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4209000	USD
CY2021Q1	akba	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	407000	USD
CY2020Q1	akba	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	445000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3007000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	4735000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-70746000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-89589000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	59000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2021Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	20000000	USD
CY2020Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	245000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19941000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	245000	USD
CY2021Q1	akba	Proceeds From Contractual Arrangement Royalties Agreement Sale Of Future Royalties ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties	44783000	USD
CY2020Q1	akba	Proceeds From Contractual Arrangement Royalties Agreement Sale Of Future Royalties ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties	0	USD
CY2021Q1	akba	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	29327000	USD
CY2020Q1	akba	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	56485000	USD
CY2021Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	367000	USD
CY2020Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	451000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	412000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	74477000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	57348000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23672000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-31996000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	231132000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	149804000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	254804000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117808000	USD
CY2021Q1	akba	Deferred Unpaid Offering Costs DeferredUnpaidOfferingCosts	171000	USD
CY2020Q1	akba	Deferred Unpaid Offering Costs DeferredUnpaidOfferingCosts	90000	USD
CY2021Q1	us-gaap	Nature Of Operations NatureOfOperations	Nature of Organization and Operations<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Akebia Therapeutics, Inc., referred to as Akebia or the Company, was incorporated in the State of Delaware in 2007. Akebia is a biopharmaceutical company with the purpose of bettering the lives of people living with kidney disease. Akebia’s lead investigational product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease, or CKD. Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, or HIF, which can lead to red blood cell, or RBC, production and improved oxygen delivery to tissues.Vadadustat is approved and marketed in Japan as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients under the trade name Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company submitted a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or FDA, for vadadustat in March of 2021 for the treatment of anemia due to CKD in adult patients with CKD on dialysis, or DD-CKD, and adult patients with CKD not on dialysis, or NDD-CKD. The Company's NDA submission did not include a Priority Review Voucher. Based on standard FDA review timelines, the FDA has a 60-day period to determine whether the NDA is complete and acceptable for review. In addition, the Company has a commercial product, Auryxia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ferric citrate), which is currently approved by the FDA and marketed for two indications in the United States: the control of serum phosphorus levels in DD-CKD adult patients and the treatment of iron deficiency anemia, or IDA, in NDD-CKD adult patients. Ferric citrate is also approved and marketed in Japan as an oral treatment for IDA in adult patients and the improvement of hyperphosphatemia in adult patients with DD-CKD and NDD-CKD under the trade name Riona (ferric citrate hydrate).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has devoted most of its resources to research and development, including its preclinical and clinical development activities, and providing general and administrative support for these operations. The Company began recording revenue from the U.S. sales of Auryxia and revenue from sublicensing rights to Auryxia in Japan to the Company’s Japanese partners Japan Tobacco, Inc. and its subsidiary Torii Pharmaceutical Co., Ltd., collectively JT and Torii, on December 12, 2018 following the consummation of a merger with Keryx Biopharmaceuticals, Inc., or Keryx, or the Merger. Additionally, following regulatory approval of vadadustat in Japan, the Company began recognizing royalty revenues from Mitsubishi Tanabe Pharma Corporation, or MTPC, from the sale of Vafseo in August 2020. In February 2021, the Company entered into a royalty interest acquisition agreement with HealthCare Royalty Partners IV, L.P., or the Royalty Agreement, whereby the Company sold its right to receive royalties and sales milestones under its Collaboration Agreement with MTPC, or the MTPC Agreement, subject to certain caps and other terms and conditions (see Note 5 for additional information). The Company has not generated a profit to date and may never generate profits from product sales. Vadadustat and the Company’s other potential product candidates are subject to long development cycles, and the Company may be unsuccessful in its efforts to develop, obtain marketing approval for or market vadadustat and its other potential product candidates. If the Company does not successfully commercialize Auryxia, vadadustat or any other potential product candidate, it may be unable to achieve profitability.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s management completed its going concern assessment in accordance with ASC 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 205-40. The Company believes that its cash resources will be sufficient to allow the Company to fund its current operating plan through at least the next twelve months from the filing of this Quarterly Report on Form 10-Q, as required by ASC 205-40. There can be no assurance, however, that the current operating plan will be achieved in the time frame anticipated by the Company, or that its cash resources will fund the Company’s operating plan for the period anticipated by the Company or that additional funding will be available on terms acceptable to the Company, or at all. The Company will require additional capital to pursue development and commercial activities related to Auryxia and vadadustat or any additional products and product candidates, including those that may be in-licensed or acquired. The Company expects to finance future cash needs through product revenue, public or private equity or debt transactions, payments from its collaborators, strategic transactions, or a combination of these approaches. However, adequate additional financing may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise capital in sufficient amounts when needed or on attractive terms, it may not be able to pursue development and commercial activities related to Auryxia and vadadustat or any additional products and product candidates, including those that may be in-licensed or acquired.</span></div>
CY2021Q1	akba	Operating Plan Sufficiently Funded By Cash Resources Period OperatingPlanSufficientlyFundedByCashResourcesPeriod	P12M
CY2021Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: prepaid and accrued research and development expense, operating lease assets and liabilities, derivative liabilities, other non-current liabilities, including the excess purchase commitment liability, stock-based compensation expense, product and collaboration revenues including various rebates and reserves related to product sales, non-cash interest expense on the liability related to sale of future royalties, inventories, income taxes, intangible assets and goodwill. The Company has made estimates of the impact of COVID-19 within the unaudited condensed consolidated financial statements and there may be changes to those estimates in future periods including changes to sales, payer mix, reserves and allowances, intangible assets and goodwill. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</span></div>
CY2020Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	41363000	USD
CY2021Q1	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	38965000	USD
CY2021Q1	akba	Valuation Allowances And Reserves Adjustments Related To Prior Period Sales ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales	-1238000	USD
CY2021Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	33661000	USD
CY2021Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	45429000	USD
CY2019Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	31543000	USD
CY2020Q1	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	33822000	USD
CY2020Q1	akba	Valuation Allowances And Reserves Adjustments Related To Prior Period Sales ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales	114000	USD
CY2020Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	32428000	USD
CY2020Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	33051000	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	44800000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	18253000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	19299000	USD
CY2021Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	37552000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5382000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	10130000	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Maximum Annual Royalty Payout Capacity ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity	13000000.0	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Maximum Aggregate Royalty Payout Capacity ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity	150000000.0	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Percentage Of Royalty Payments To Be Received Contingent On Reaching Maximum Annual Royalty Payout Capacity ContractualArrangementRoyaltiesAgreementPercentageOfRoyaltyPaymentsToBeReceivedContingentOnReachingMaximumAnnualRoyaltyPayoutCapacity	0.85
CY2021Q1	akba	Proceeds From Contractual Arrangement Royalties Agreement Sale Of Future Royalties ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties	44800000	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Proceeds Contingent On Annual Sales Milestones ContractualArrangementRoyaltiesAgreementProceedsContingentOnAnnualSalesMilestones	5000000.0	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Interest Rate Effective Percentage ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage	0.193
CY2020Q4	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	0	USD
CY2021Q1	akba	Proceeds From Contractual Arrangement Royalties Agreement Sale Of Future Royalties ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties	44783000	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Royalties Earned And Payable ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable	20000	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Noncash Interest Expense Income ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome	2162000	USD
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	46925000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	252765000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	252765000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	19996000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	19999000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	19999000	USD
CY2021Q1	akba	Cash Cash Equivalents And Short Term Investments Amortized Cost CashCashEquivalentsAndShortTermInvestmentsAmortizedCost	272761000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	3000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2021Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	272764000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	228698000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	228698000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	39979000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	13000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	39992000	USD
CY2020Q4	akba	Cash Cash Equivalents And Short Term Investments Amortized Cost CashCashEquivalentsAndShortTermInvestmentsAmortizedCost	268677000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	13000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2020Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	268690000	USD
CY2021Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1621000	USD
CY2021Q1	akba	Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year One DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne	0	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	19999000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	0	security
CY2021Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	0	security
CY2020Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	2420000	USD
CY2021Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	80000	USD
CY2020Q1	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	2500000	USD
CY2020Q4	akba	Accrued Commercial Manufacturing Current AccruedCommercialManufacturingCurrent	514000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2542000	USD
CY2021Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	64999000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	64076000	USD
CY2021Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	6524000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	19691000	USD
CY2021Q1	akba	Inventory Net Current And Non Current InventoryNetCurrentAndNonCurrent	73144000	USD
CY2020Q4	akba	Inventory Net Current And Non Current InventoryNetCurrentAndNonCurrent	86309000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	44806000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	61017000	USD
CY2021Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	28338000	USD
CY2020Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	25292000	USD
CY2021Q1	akba	Inventory Net Current And Non Current InventoryNetCurrentAndNonCurrent	73144000	USD
CY2020Q4	akba	Inventory Net Current And Non Current InventoryNetCurrentAndNonCurrent	86309000	USD
CY2021Q1	us-gaap	Inventory Write Down InventoryWriteDown	5100000	USD
CY2020Q1	us-gaap	Inventory Write Down InventoryWriteDown	100000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	214148000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	69438000	USD
CY2020Q4	akba	Finite Lived Intangible Assets Adoption Adjustment FiniteLivedIntangibleAssetsAdoptionAdjustment	-540000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	144170000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9000000.0	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9100000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	55100000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	55100000	USD
CY2021Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q1	akba	Accrued Product Revenue Allowances Current AccruedProductRevenueAllowancesCurrent	38786000	USD
CY2020Q4	akba	Accrued Product Revenue Allowances Current AccruedProductRevenueAllowancesCurrent	38049000	USD
CY2021Q1	akba	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	32085000	USD
CY2020Q4	akba	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	28986000	USD
CY2021Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6185000	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	14402000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5429000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5286000	USD
CY2021Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2510000	USD
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2998000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1374000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3271000	USD
CY2021Q1	akba	Accrued Commercial Manufacturing Current AccruedCommercialManufacturingCurrent	855000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8644000	USD
CY2021Q1	us-gaap	Postemployment Benefits Liability Current PostemploymentBenefitsLiabilityCurrent	448000	USD
CY2020Q4	us-gaap	Postemployment Benefits Liability Current PostemploymentBenefitsLiabilityCurrent	497000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	11754000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	123889000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	130624000	USD
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	158520089	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	158520089	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	148074085	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	148074085	shares
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	27437323	shares
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	23566853	shares
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5992000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4916000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5992000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4916000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1700000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1700000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1800000	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1700000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	4896000	USD
CY2021Q1	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	1349000	USD
CY2021Q1	akba	Lessee Operating Lease Liability Payments Net Reminder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsNetReminderOfFiscalYear	3547000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	7322000	USD
CY2021Q1	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	1824000	USD
CY2021Q1	akba	Lessee Operating Lease Liability Payments Due Net Year One LesseeOperatingLeaseLiabilityPaymentsDueNetYearOne	5498000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5947000	USD
CY2021Q1	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	307000	USD
CY2021Q1	akba	Lessee Operating Lease Liability Payments Due Net Year Two LesseeOperatingLeaseLiabilityPaymentsDueNetYearTwo	5640000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5739000	USD
CY2021Q1	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	0	USD
CY2021Q1	akba	Lessee Operating Lease Liability Payments Due Net Year Three LesseeOperatingLeaseLiabilityPaymentsDueNetYearThree	5739000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5817000	USD
CY2021Q1	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	0	USD
CY2021Q1	akba	Lessee Operating Lease Liability Payments Due Net Year Four LesseeOperatingLeaseLiabilityPaymentsDueNetYearFour	5817000	USD
CY2021Q1	akba	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	4104000	USD
CY2021Q1	akba	Lessor Operating Lease Payment To Be Received Due After Year Four LessorOperatingLeasePaymentToBeReceivedDueAfterYearFour	0	USD
CY2021Q1	akba	Lessee Operating Lease Liability Payments Due Net After Year Four LesseeOperatingLeaseLiabilityPaymentsDueNetAfterYearFour	4104000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	33825000	USD
CY2021Q1	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	3480000	USD
CY2021Q1	akba	Lessee Operating Lease Liability Payments Due Net LesseeOperatingLeaseLiabilityPaymentsDueNet	30345000	USD
CY2021Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross	192300000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	33825000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5179000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	28646000	USD
CY2021Q1	akba	Purchase Committed Program Remaining Contract Costs PurchaseCommittedProgramRemainingContractCosts	8300000	USD
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18402397	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16617256	shares

Files In Submission

Name	View Source	Status
0001628280-21-009696-index-headers.html	Edgar Link	pending
0001628280-21-009696-index.html	Edgar Link	pending
0001628280-21-009696.txt	Edgar Link	pending
0001628280-21-009696-xbrl.zip	Edgar Link	pending
akba-20210331.htm	Edgar Link	pending
akba-20210331.xsd	Edgar Link	pending
akba-20210331_cal.xml	Edgar Link	unprocessable
akba-20210331_def.xml	Edgar Link	unprocessable
akba-20210331_htm.xml	Edgar Link	completed
akba-20210331_lab.xml	Edgar Link	unprocessable
akba-20210331_pre.xml	Edgar Link	unprocessable
exhibit104-q12021.htm	Edgar Link	pending
exhibit105-q12021.htm	Edgar Link	pending
exhibit311-q12021.htm	Edgar Link	pending
exhibit312-q12021.htm	Edgar Link	pending
exhibit321-q12021.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AKBA
Akebia Therapeutics, Inc. Stock $akba

2021 Q1 Form 10-Q Financial Statement

#000162828021009696 Filed on May 10, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AKBA Akebia Therapeutics, Inc. Stock $akba

2021 Q1 Form 10-Q Financial Statement

#000162828021009696 Filed on May 10, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AKBA
Akebia Therapeutics, Inc. Stock $akba